Reporting Challenge
Work through structured reporting decisions and compare your conclusions with the supplied model report. Select a case to practise a specific reporting context.
What you will practise
- Choose the relevant findings for the report.
- Build a consistent interpretation.
- Compare the final summary with the model report.
Choose a case
Each case includes staged questions and an end-of-case debrief.
Staging FDG PET/CT — Hodgkin lymphoma
Assemble a structured report. Choose the best phrasing for each section, then compare with the model report.
Melanoma on Immunotherapy: FDG PET/CT
A patient with metastatic cutaneous melanoma on anti-PD-1 therapy returns for restaging ¹⁸F-FDG PET/CT. A baseline study is available. Choose the best phrasing for each section as you build a response report that will not over-call immune-related inflammation as progression.
NET Receptor PET: Theranostic Selection
A patient with metastatic well-differentiated neuroendocrine tumor undergoes ⁶⁸Ga-DOTATATE PET/CT to assess suitability for ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy. Choose the best phrasing for each section of a theranostic-selection report.
EOT PET/CT in Hodgkin Lymphoma
A 28-year-old with advanced classical Hodgkin lymphoma has completed chemotherapy. An end-of-treatment FDG-PET/CT is performed to assess response and decide whether consolidative radiotherapy is needed. Choose the best phrasing for each part of the report.
Baseline Staging PET/CT in DLBCL
A 61-year-old with newly diagnosed diffuse large B-cell lymphoma is referred for baseline FDG-PET/CT staging before R-CHOP. Choose the best phrasing for each part of the report.
RECIP 1.0 on PSMA PET
A man with mCRPC on 177Lu-PSMA radioligand therapy returns for an interim 68Ga-PSMA PET/CT compared with his pre-therapy baseline. Most deposits have shrunk and become less avid, whole-body PSMA-positive tumour volume is clearly lower, and there are no new lesions — but one paraspinal node is larger and hotter. Build a RECIP 1.0 response report that reads reproducibly and does not overcall progression on one discordant lesion.
223Ra Bone Flare Report
A man with osteoblastic mCRPC has a follow-up bone study 8 weeks after cycle 1 of 223Ra. Two new foci appear that were not on the baseline scan, but previously known lesions look less intense, ALP has fallen and bone pain has improved. Write a report that distinguishes a possible osteoblastic flare from true progression.